Business Context and Reporting Period
Company: Tempus AI, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Tempus is a healthcare technology company focused on precision medicine through "Intelligent Diagnostics." It operates a vertically integrated platform combining laboratory testing (Genomics), data licensing (Data and Services), and algorithmic diagnostics (AI Applications). The company connects clinical, molecular, and imaging data to personalize patient care and support drug development.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Net Revenue | $693.4 million | $531.8 million |
| Net Loss | $(705.8) million | $(214.1) million |
| Adjusted EBITDA | $(104.7) million | $(154.2) million |
| Cash and Cash Equivalents | $341.8 million | $166.6 million |
| Total Debt (Principal) | $440.6 million | $272.4 million (Term Loan only) |
| Accumulated Deficit | $(2.2) billion | $(1.4) billion |
Note: Debt figures for 2024 include the Convertible Promissory Note ($168.2M) and Term Loan Facility ($272.4M). Subsequent to year-end, additional debt was incurred for the Ambry acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30% year-over-year.
- Genomics: Revenue rose 24% to $451.7 million, driven by a 24% increase in oncology NGS test volume (270,800 tests) and higher average reimbursement ($1,510 vs. $1,450).
- Data and Services: Revenue rose 43% to $241.6 million, driven by increased demand for Insights products and the reversal of warrant contract asset amortization following the AstraZeneca warrant termination.
- Expense Surge: Operating expenses increased significantly, primarily due to the Initial Public Offering (IPO) in June 2024.
- Stock-Based Compensation (SBC): Total SBC expense was $534.1 million in 2024 (compared to $0 in 2023), as the liquidity event condition for pre-IPO RSUs was satisfied.
- Selling, General & Administrative (SG&A): Increased 155% to $755.4 million, largely due to $405.9 million in SBC and public company costs.
- Strategic Transactions:
- IPO: Completed in June 2024, raising $382.0 million in net proceeds.
- Ambry Acquisition: Agreed in November 2024 to acquire Ambry Genetics Corporation for $375 million cash plus stock; closed February 2025.
- Joint Venture: Formed SB Tempus Corp. with SoftBank in July 2024 to expand operations in Japan.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue investing heavily in R&D, technology, and commercial expansion. The company anticipates continued operating losses as it scales its platform and expands into new disease areas (cardiology, neuropsychiatry) and geographies.
- Reimbursement Strategy: A key focus is improving average reimbursement rates for Genomics tests through FDA approvals (e.g., xT CDX assay) and engagement with Medicare Administrative Contractors (MACs).
- Key Risks:
- Profitability: The company has incurred significant losses since inception and may not achieve profitability in the foreseeable future.
- Reimbursement: Revenue is heavily dependent on third-party payer coverage. Changes in Medicare or commercial payer policies could materially impact results.
- Regulatory: Subject to extensive FDA regulation regarding Laboratory Developed Tests (LDTs) and medical devices. New FDA rules on LDTs are being phased in.
- Debt Covenants: The company must maintain minimum liquidity ($25 million) and specific revenue thresholds ($1.0 billion - $1.1 billion trailing twelve months) under its credit agreement.
- Legal Proceedings: Facing a patent infringement lawsuit from Guardant Health regarding liquid biopsy technology and ongoing government investigations into billing practices (False Claims Act/Anti-Kickback).
Investor Verification Checklist
- Reimbursement Rates: Verify the sustainability of the increased average reimbursement per NGS test ($1,510) and the success of ongoing appeals with payers.
- Debt Capacity: Confirm compliance with the new revenue covenants ($1.0B - $1.1B) following the Ambry acquisition and additional debt financing.
- Stock-Based Compensation: Assess the impact of the one-time $534 million SBC charge on future expense baselines and the remaining unrecognized SBC ($151.6 million).
- Legal Exposure: Monitor the status of the Guardant Health patent litigation and the outcome of the U.S. Attorney's Office investigation into billing practices.
- Ambry Integration: Evaluate the integration progress and financial impact of the Ambry Genetics acquisition post-closing.